Schrag A - Search Results

1

Iodine-123-iodo-lisuride SPECT in Parkinson's disease.

Cordes M, Hierholzer J, Schelosky L, Schrag A, Richter WS, Eichstädt H, Schulze PE, Poewe W, Felix R. Cordes M, et al. Among authors: schrag a. J Nucl Med. 1996 Jan;37(1):22-5. J Nucl Med. 1996. PMID: 8543995 Free article.

2

[Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls].

Hierholzer J, Cordes M, Schelosky L, Richter W, Schrag A, Poewe W, Schulze PE, Semmler W, Eichstädt H, Felix R. Hierholzer J, et al. Among authors: schrag a. Nuklearmedizin. 1995 Aug;34(4):141-5. Nuklearmedizin. 1995. PMID: 7675643 German.

3

[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].

Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W. Eichhorn TE, et al. Among authors: schrag a. Nervenarzt. 1995 Dec;66(12):933-41. Nervenarzt. 1995. PMID: 8584079 German.

4

Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease.

Ebersbach G, Trottenberg T, Hättig H, Schelosky L, Schrag A, Poewe W. Ebersbach G, et al. Among authors: schrag a. Brain. 1996 Feb;119 ( Pt 1):79-87. doi: 10.1093/brain/119.1.79. Brain. 1996. PMID: 8624696

5

[Magnetic resonance tomography in patients with Parkinson's disease and Parkinson-plus syndromes].

Hierholzer J, Schrag A, Cordes M, Sander B, Schelosky L, Harisch C, Venz S, Keske U, Mäurer J, Poewe W, Felix R. Hierholzer J, et al. Among authors: schrag a. Rofo. 1996 Jul;165(1):43-51. doi: 10.1055/s-2007-1015712. Rofo. 1996. PMID: 8765362 German.

6

The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.

Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F. Schrag AE, et al. Clin Neuropharmacol. 1998 May-Jun;21(3):169-75. Clin Neuropharmacol. 1998. PMID: 9617508 Clinical Trial.

7

Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges.

Schrag A, Schelosky L, Scholz U, Poewe W. Schrag A, et al. Mov Disord. 1999 Mar;14(2):252-5. doi: 10.1002/1531-8257(199903)14:2<252::aid-mds1009>3.0.co;2-n. Mov Disord. 1999. PMID: 10091618 Clinical Trial.

8

Minimal clinically important change on the unified Parkinson's disease rating scale.

Schrag A, Sampaio C, Counsell N, Poewe W. Schrag A, et al. Mov Disord. 2006 Aug;21(8):1200-7. doi: 10.1002/mds.20914. Mov Disord. 2006. PMID: 16673410

9

Depression rating scales in Parkinson's disease: critique and recommendations.

Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, Weintraub D, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Schrag A, et al. Mov Disord. 2007 Jun 15;22(8):1077-92. doi: 10.1002/mds.21333. Mov Disord. 2007. PMID: 17394234 Free PMC article.

10

Scales to assess sleep impairment in Parkinson's disease: critique and recommendations.

Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B, Trenkwalder C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Schrag A, Goetz CG. Högl B, et al. Among authors: schrag a. Mov Disord. 2010 Dec 15;25(16):2704-16. doi: 10.1002/mds.23190. Mov Disord. 2010. PMID: 20931631 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

362 results

Search Page

Filters